First patient dosed with Charcot-Marie-Tooth disease treatment
Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain,… Read More
